推荐产品
等級
pharmaceutical primary standard
API 家族
leflunomide
製造商/商標名
EDQM
應用
pharmaceutical (small molecule)
格式
neat
SMILES 字串
Cc1oncc1C(=O)Nc2ccc(cc2)C(F)(F)F
InChI
1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)
InChI 密鑰
VHOGYURTWQBHIL-UHFFFAOYSA-N
基因資訊
human ... DHODH(1723)
正在寻找类似产品? 访问 产品对比指南
相关类别
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Leflunomide for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
相關產品
产品编号
说明
价格
訊號詞
Danger
危險分類
Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
標靶器官
Respiratory system
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類(WGK)
WGK 1
閃點(°F)
Not applicable
閃點(°C)
Not applicable
American journal of physiology. Regulatory, integrative and comparative physiology, 303(11), R1136-R1146 (2012-10-27)
The aryl hydrocarbon receptor (AHR) has emerged as a major modulator of inflammatory processes. We tested the hypothesis that AHR activation protects the ischemic-reperfused kidney in association with the suppression of the inflammatory response. Accordingly, male mice were treated with
The Journal of rheumatology, 40(3), 228-235 (2013-01-17)
To assess the safety of treating patients with rheumatoid arthritis with a combination of methotrexate (MTX) and leflunomide (LEF) in comparison to MTX monotherapy, in clinical practice. The Safety of Methotrexate in Combination with Leflunomide in Rheumatoid Arthritis (SMILE) study
The Annals of pharmacotherapy, 47(3), e15-e15 (2013-03-01)
To study the pharmacokinetics and pharmacogenetics of leflunomide and document its efficacy and safety in the treatment of inflammatory arthritis in a patient with end-stage renal disease (ESRD) who was on peritoneal dialysis. Therapy for a 78-year-old man with ESRD
Arthritis care & research, 65(3), 464-470 (2012-10-09)
To determine the "real-world" clinical effectiveness and safety of leflunomide in patients with psoriatic arthritis (PsA). This prospective, multinational 24-week observational study involved adult patients with active PsA who initiated treatment with leflunomide. Patients were evaluated at baseline, 12 weeks
Annals of the rheumatic diseases, 72(6), 1011-1017 (2012-08-14)
To evaluate a vasculitis centre based management strategy for eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA). A retrospective cohort study at a vasculitis referral centre was performed. All EGPA patients admitted from 1990 to 2009 were included. A structured interdisciplinary work-up
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门